IRCT20220809055645N7 IRCT 2024-02-17 Rasht University of Medical Sciences The effect of Empagliflozin on outcomes of patients with myocardial infarction undergoing primary PCI Investigating the effect of Empagliflozin on outcomes of patients with myocardial infarction undergoing primary Percutaneous coronary intervention (PCI):a randomized double-blind clinical trial with placebo 2024-03-05 anticipated 54 Complete https://irct.ir/trial/75261 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: In this study, 54 patients according to inclusion criteria, with block randomization group with 1:1 ratio as 2 groups(A: intervention and B: placebo) will enter this study. with Blocking randomization we give each patient a number from 1 to 54. Then a table with 9 rows named block that each block has 6 segments, will be considered and then the numbers will be placed respectively in the rows. After all numbers placed in blocks, all patients with code A, receive drug andpatients with code B receive placebo. https://www.sealedenvelope.com is used for randomization, Blinding description: Patients and researchers are blind. A third person out of the study, based on randomization allocates the placebo and drug to researcher. 3 ST Elevation myocardial infarction. Intervention 1: Intervention group: Receiving Empagliflozin 10 mg 1 tablet daily. Made by Actover co. Intervention 2: Control group: Receiving Placebo (cellulose micro crystal tablet). 1 tablet daily. Yes - There is a plan to make this available What will be shared: All data except personal information (name, contact number, file number) can be published. When: After publishing the results To whom: Available to service providers such as doctors and nurses. Conditions: After obtaining permission from the project manager, the information will be usable. Where to obtain: Project manager How to obtain: By email to the project manager Comments: -